Kirkland Represents GI Partners Fund VI on Acquisition of Clinical Ink Alongside Ardan Equity

Kirkland & Ellis advised GI Partners Fund VI on its acquisition of Clinical Ink, Inc., a global clinical trial technology company, alongside Ardan Equity, a private equity firm specializing in healthcare technology. Drawing on their complementary life sciences and healthcare technology expertise, Ardan and GI will collaborate closely with management to continue to scale the Clinical Ink platform globally, pursue opportunities across clinical research and care, and deliver innovative solutions that meet the rapidly evolving needs of the industry, while maintaining the highest standards of quality and compliance.

Read the transaction press release

The Kirkland team included corporate lawyers Stuart Casillas, Vlad Kroll, Walton Dumas, Connor O’Flaherty, EJ Chang, Tommy Antonino and Jennifer Leserman; debt finance lawyers Scott Rolnik, Brock Baker, Connor Guilfoyle, Erik Hepler, Katie Schneller, Shana Hamilton and Nooreen Sandhu; healthcare transactions lawyers Will Richmond and Sana Shakir; investment funds regulatory lawyer Phil Giglio; investment funds ERISA lawyers Joe Lifsics and Christine Matott; investment funds lawyers Jordan Mulder, Isabelle Ng, Andrew Wool and Christopher Wynne; tax lawyers Heidi Yuen and Ally Nelson; technology & IP transactions lawyers John Lynn, Roxana Azar, Danielle Lee and Cordelia Mikita; antitrust & competition lawyers Stephen Mohr, Mark Gardner, Mike Thorpe and Sophie Vinicombe; employment & labor lawyers Erin Davey and Kevin Miller; employee benefits lawyers Jack Amaro and Nick Carballo; executive compensation lawyers Rohit Nafday and Lilibeth Clelo-Garcha; real estate lawyer Rob Miceli; and capital markets lawyer Bob Goedert.